Pathology of pulmonary hypertension.

[1]  M. Humbert,et al.  Inflammation in pulmonary arterial hypertension , 2003, European Respiratory Journal.

[2]  P. Sehgal,et al.  Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nef-infected macaques. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[3]  J. Behr,et al.  Pulmonary hypertension in interstitial lung disease , 2008, European Respiratory Journal.

[4]  P. Luciw,et al.  HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. , 2006, American journal of respiratory and critical care medicine.

[5]  I. Fantozzi,et al.  Bone Morphogenetic Protein-2 Upregulates Expression and Function of Voltage-gated K + Channels in Human Pulmonary Artery Smooth Muscle Cells , 2022 .

[6]  S. Archer,et al.  An Abnormal Mitochondrial–Hypoxia Inducible Factor-1&agr;–Kv Channel Pathway Disrupts Oxygen Sensing and Triggers Pulmonary Arterial Hypertension in Fawn Hooded Rats: Similarities to Human Pulmonary Arterial Hypertension , 2006, Circulation.

[7]  M. Frid,et al.  Role of the adventitia in pulmonary vascular remodeling. , 2006, Physiology.

[8]  V. Peinado,et al.  Identification of vascular progenitor cells in pulmonary arteries of patients with chronic obstructive pulmonary disease. , 2006, American journal of respiratory cell and molecular biology.

[9]  N. Voelkel,et al.  Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension. , 2006, Chest.

[10]  D. Stewart,et al.  Bone Morphogenetic Protein Receptor-2 Signaling Promotes Pulmonary Arterial Endothelial Cell Survival: Implications for Loss-of-Function Mutations in the Pathogenesis of Pulmonary Hypertension , 2006, Circulation research.

[11]  F. Jenkins,et al.  No Role for Kaposi Sarcoma‐Associated Herpesvirus in Pediatric Idiopathic Pulmonary Hypertension , 2006, Pediatric pulmonology.

[12]  M. Frid,et al.  Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. , 2006, The American journal of pathology.

[13]  T. Schulz,et al.  Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. , 2005, American journal of respiratory and critical care medicine.

[14]  D. Badesch,et al.  Autoimmunity and pulmonary hypertension: a perspective , 2005, European Respiratory Journal.

[15]  A. Zaiman,et al.  One hundred years of research in the pathogenesis of pulmonary hypertension. , 2005, American journal of respiratory cell and molecular biology.

[16]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[17]  W. Seeger,et al.  Imatinib for the treatment of pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[18]  F. Fedele,et al.  Human Herpesvirus 8 and Pulmonary Hypertension , 2005, Emerging infectious diseases.

[19]  J. Loscalzo,et al.  Increased Susceptibility to Pulmonary Hypertension in Heterozygous BMPR2-Mutant Mice , 2005, Circulation.

[20]  P. Jones,et al.  Epidermal Growth Factor Receptor Blockade Mediates Smooth Muscle Cell Apoptosis and Improves Survival in Rats With Pulmonary Hypertension , 2005, Circulation.

[21]  N. Voelkel,et al.  Initial apoptosis is followed by increased proliferation of apoptosis‐resistant endothelial cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  S. Archer,et al.  Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. , 2005, The Journal of clinical investigation.

[23]  N. Rudarakanchana,et al.  Dysfunctional Smad Signaling Contributes to Abnormal Smooth Muscle Cell Proliferation in Familial Pulmonary Arterial Hypertension , 2005, Circulation research.

[24]  C. Munaut,et al.  Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension , 2005, European Respiratory Journal.

[25]  D. Stewart,et al.  Rescue of Monocrotaline-Induced Pulmonary Arterial Hypertension Using Bone Marrow–Derived Endothelial-Like Progenitor Cells: Efficacy of Combined Cell and eNOS Gene Therapy in Established Disease , 2005, Circulation research.

[26]  T. Sata,et al.  Lack of human herpesvirus 8 infection in lungs of Japanese patients with primary pulmonary hypertension. , 2005, The Journal of infectious diseases.

[27]  M. Malloy,et al.  Kaposi sarcoma-associated herpesvirus and primary and secondary pulmonary hypertension. , 2005, Chest.

[28]  K. Dingemans,et al.  The ultrastructure of the various forms of pulmonary arterial intimal fibrosis , 1979, Virchows Archiv A.

[29]  J. Moorman,et al.  Hepatitis C virus and the lung: implications for therapy. , 2005, Chest.

[30]  A. Zaiman,et al.  Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[31]  T. Smithgall,et al.  HIV-1 Nef Promotes Survival of TF-1 Macrophages by Inducing Bcl-XL Expression in an Extracellular Signal-regulated Kinase-dependent Manner* , 2004, Journal of Biological Chemistry.

[32]  M. Humbert,et al.  Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[33]  S. P. Nana-Sinkam,et al.  Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[34]  R. Iyengar,et al.  Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. , 2004, The Journal of clinical investigation.

[35]  M. Humbert,et al.  Pathologic assessment of vasculopathies in pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[36]  R. Sittiwangkul,et al.  Cardiac manifestations in HIV-infected Thai children , 2004, Annals of tropical paediatrics.

[37]  O. Fackler,et al.  Human Immunodeficiency Virus Type 1 Nef Activates p21-Activated Kinase via Recruitment into Lipid Rafts , 2004, Journal of Virology.

[38]  V. Bond,et al.  Extracellular Nef Protein Targets CD4+ T Cells for Apoptosis by Interacting with CXCR4 Surface Receptors , 2004, Journal of Virology.

[39]  N. Voelkel,et al.  Oxidative stress in severe pulmonary hypertension. , 2004, American journal of respiratory and critical care medicine.

[40]  R. Budhiraja,et al.  Endothelial Dysfunction in Pulmonary Hypertension , 2004, Circulation.

[41]  J. Yuan,et al.  Activation of K+ channels: an essential pathway in programmed cell death. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[42]  R. Kennedy,et al.  Is HIV involved in the pathogenesis of non-infectious pulmonary complications in infected patients? , 2003, Current HIV research.

[43]  K. Brown,et al.  Expression of human herpesvirus 8 in primary pulmonary hypertension. , 2003, The New England journal of medicine.

[44]  A. Di Matteo,et al.  Clinical and therapeutical follow-up of HIV-associated pulmonary hypertension: prospective study of 10 patients , 2003, AIDS.

[45]  E. Tschachler,et al.  Kaposi's Sarcoma-Like Tumors in a Human Herpesvirus 8 ORF74 Transgenic Mouse , 2003, Journal of Virology.

[46]  M. Axthelm,et al.  A G Protein-Coupled Receptor Encoded by Rhesus Rhadinovirus Is Similar to ORF74 of Kaposi's Sarcoma-Associated Herpesvirus , 2003, Journal of Virology.

[47]  S. Rafii,et al.  Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. , 2003, Cancer cell.

[48]  J. Jäger,et al.  HIV-1 Nef induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-kappa B activation. , 2003, Journal of immunology.

[49]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[50]  M. Humbert,et al.  Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension , 2002, Nature Medicine.

[51]  M. Frid,et al.  Mature Vascular Endothelium Can Give Rise to Smooth Muscle Cells via Endothelial-Mesenchymal Transdifferentiation: In Vitro Analysis , 2002, Circulation research.

[52]  M. Humbert,et al.  CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension , 2002 .

[53]  R. Trembath,et al.  Primary Pulmonary Hypertension Is Associated With Reduced Pulmonary Vascular Expression of Type II Bone Morphogenetic Protein Receptor , 2002, Circulation.

[54]  V. Peinado,et al.  Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD , 2002, European Respiratory Journal.

[55]  B. Peterlin,et al.  Interaction between Nef and phosphatidylinositol-3-kinase leads to activation of p21-activated kinase and increased production of HIV. , 2002, Virology.

[56]  M. Humbert,et al.  Chemokine RANTES in severe pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[57]  A. Zaiman,et al.  Prostacyclin analogs as the brakes for pulmonary artery smooth muscle cell proliferation: is it sufficient to treat severe pulmonary hypertension? , 2002, American journal of respiratory cell and molecular biology.

[58]  W. Travis,et al.  Immunohistochemical study of endothelin-1 and matrix metalloproteinases in plexogenic pulmonary arteriopathy. , 2002, Pathology, research and practice.

[59]  R. Speich,et al.  Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. , 2001, Swiss medical weekly.

[60]  D. Stewart,et al.  Cell-Based Gene Transfer of Vascular Endothelial Growth Factor Attenuates Monocrotaline-Induced Pulmonary Hypertension , 2001, Circulation.

[61]  M. Humbert,et al.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. , 2001, The Journal of clinical investigation.

[62]  G. Semenza,et al.  Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis , 2001, The Journal of pathology.

[63]  N. Voelkel,et al.  The pathobiology of pulmonary hypertension. Endothelium. , 2001, Clinics in chest medicine.

[64]  R. Trembath,et al.  Altered Growth Responses of Pulmonary Artery Smooth Muscle Cells From Patients With Primary Pulmonary Hypertension to Transforming Growth Factor-&bgr;1 and Bone Morphogenetic Proteins , 2001, Circulation.

[65]  A. Chaouat,et al.  "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. , 2001, American journal of respiratory and critical care medicine.

[66]  N. Voelkel,et al.  Severe pulmonary hypertension after the discovery of the familial primary pulmonary hypertension gene. , 2001, The European respiratory journal.

[67]  N. Voelkel,et al.  Genomic approaches to research in pulmonary hypertension , 2001, Respiratory research.

[68]  R. Desrosiers,et al.  Simian homologues of human herpesvirus 8. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[69]  D A Lynch,et al.  Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. , 2001, American journal of respiratory and critical care medicine.

[70]  P. Hirth,et al.  Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[71]  R. Nagai,et al.  Vascular smooth muscle cell phenotypes in primary pulmonary hypertension. , 2001, The European respiratory journal.

[72]  N. Voelkel,et al.  Microsatellite Instability of Endothelial Cell Growth and Apoptosis Genes Within Plexiform Lesions in Primary Pulmonary Hypertension , 2001, Circulation research.

[73]  G. Barbarini,et al.  Primary Pulmonary Hypertension in HIV Patients: A Systematic Review , 2001, Angiology.

[74]  Jun Yamashita,et al.  Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors , 2000, Nature.

[75]  P. Friedman,et al.  Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. , 2000, American journal of respiratory and critical care medicine.

[76]  S. Hodge,et al.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.

[77]  M. d’Ortho,et al.  Inhibition of Matrix Metalloproteinases by Lung TIMP-1 Gene Transfer or Doxycycline Aggravates Pulmonary Hypertension in Rats , 2000, Circulation research.

[78]  K. Lesch,et al.  Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. , 2000, The Journal of clinical investigation.

[79]  Adrian M Heilbut,et al.  Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor , 2000, Nature Medicine.

[80]  Tong-Yuan Yang,et al.  Transgenic Expression of the Chemokine Receptor Encoded by Human Herpesvirus 8 Induces an Angioproliferative Disease Resembling Kaposi's Sarcoma , 2000, The Journal of experimental medicine.

[81]  D. Trono,et al.  The Nef protein of HIV-1 associates with rafts and primes T cells for activation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[82]  P. Jones,et al.  Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. , 2000, The Journal of clinical investigation.

[83]  N. Voelkel,et al.  Severe pulmonary hypertensive diseases: a perspective. , 1999, The European respiratory journal.

[84]  R. L. Williams,et al.  Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. , 1999, The American journal of pathology.

[85]  M. Rabinovitch.  EVE and beyond, retro and prospective insights. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[86]  D. Badesch,et al.  Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[87]  N. Voelkel,et al.  Primary pulmonary hypertension between inflammation and cancer. , 1998, Chest.

[88]  M. Humbert,et al.  Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. , 1998, The European respiratory journal.

[89]  K. Shroyer,et al.  Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. , 1998, The Journal of clinical investigation.

[90]  M. Frid,et al.  Smooth muscle cells isolated from discrete compartments of the mature vascular media exhibit unique phenotypes and distinct growth capabilities. , 1997, Circulation research.

[91]  R. Desrosiers,et al.  A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus , 1997, Journal of virology.

[92]  C. Boshoff,et al.  Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. , 1997, Science.

[93]  N. Voelkel,et al.  Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. , 1997, Human pathology.

[94]  P. Jones,et al.  Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. , 1997, The American journal of pathology.

[95]  D. Schuster,et al.  The role of vascular injury and hemodynamics in rat pulmonary artery remodeling. , 1996, The Journal of clinical investigation.

[96]  E. Medico,et al.  The HIV-1 Nef Protein Interferes with Phosphatidylinositol 3-Kinase Activation 1 (*) , 1996, The Journal of Biological Chemistry.

[97]  M. Harris.  The role of myristoylation in the interactions between human immunodeficiency virus type I Nef and cellular proteins. , 1995, Biochemical Society transactions.

[98]  A Giaid,et al.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.

[99]  M. Humbert,et al.  Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. , 1995, American journal of respiratory and critical care medicine.

[100]  V. S. Zhdanov,et al.  Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. , 1995, The American journal of pathology.

[101]  J L Sullivan,et al.  Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. , 1995, The New England journal of medicine.

[102]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[103]  L. Gold,et al.  Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. , 1994, The American journal of pathology.

[104]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[105]  H. Palevsky,et al.  Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. , 1992, The American review of respiratory disease.

[106]  R. Desrosiers,et al.  Importance of the nef gene for maintenance of high virus loads and for development of AIDS , 1991, Cell.

[107]  D. Moodie,et al.  Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. , 1991, Journal of the American College of Cardiology.

[108]  M. Yacoub,et al.  The histopathology of 36 cases of plexogenic pulmonary arteriopathy , 1990, Histopathology.

[109]  H. Palevsky,et al.  Classification of Histologic Lesions in Primary Pulmonary Hypertension Group Medial lesions Intimal lesions Medial hypertrophy Increased smooth muscle , 2005 .

[110]  J. Gosney,et al.  Ultrastructure of early plexogenic pulmonary arteriopathy , 1988, Histopathology.

[111]  S. Factor,et al.  Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. , 1987, Human pathology.

[112]  C. Wagenvoort,et al.  Comparison of primary plexogenic arteriopathy in adults and children. A morphometric study in 40 patients. , 1985, British heart journal.

[113]  Meyrick Bo,et al.  Crotalaria-induced pulmonary hypertension. Uptake of 3H-thymidine by the cells of the pulmonary circulation and alveolar walls. , 1982 .

[114]  B. Meyrick,et al.  Crotalaria-induced pulmonary hypertension. Uptake of 3H-thymidine by the cells of the pulmonary circulation and alveolar walls. , 1982, The American journal of pathology.

[115]  L. Reid,et al.  Hypoxia and incorporation of 3H-thymidine by cells of the rat pulmonary arteries and alveolar wall. , 1979, The American journal of pathology.

[116]  L. Reid,et al.  Comparison of primary and thromboembolic pulmonary hypertension. , 1972, Thorax.